Fresh analysis indicates that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who end traditional diet and exercise plans.
Findings released in a leading medical journal shows that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing such treatments should be aware of the risk of quick rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain means a return to original mass in about a year and a half.
Weighing Therapies
The research, which reviewed 37 of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
Researchers point out that individuals who shed pounds through diet and exercise usually have a more gradual weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the injections explains the heightened weight return.
The injections mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, given the significant potential of weight regain, the treatment is often long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the chronic nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have stopped the jabs explain a powerful return of cravings.
"It was like a switch flipping and you're instantly starving," recalled a patient.
This difficulty is compounded if patients have not adopted lasting lifestyle or habit changes during therapy.
Significant Adoption
Survey data indicate that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Use is greater among women compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians caution that while these medications are powerful agents for weight loss, they are not a permanent cure and maintained weight loss likely depends on combined behavioural support.
